Francesca Giunchi Featured Researcher
April 1, 2014

Francesca Giunchi Featured Researcher

A board certified pathologist at the S.Orsola-Malpighi teaching Hospital of the University of Bologna, Italy, Dr. Francesca Giunchi focuses on the study of prostate pathology with a particular interest in prostate cancer. Dr. Giunchi’s main research interests are the relationship between inflammatory/atrophic lesions and prostate cancer, histological Gleason grading and the histological features predictive of indolent versus lethal prostate cancer. She received a Postdoctoral Training Award 2013 entitled, "Inflammatory lesion and prostate cancer".

Over the past 5 years, Dr. Giunchi participated in several collaborative projects on prostate cancer and prostate inflammatory lesions within TopCap at the University of Orebro and Uppsala in Sweden and the Harvard School of Public Health in Boston. Specifically, she has been conducting a histological review of prostate cancer cohorts from the US, (Health Professionals Follow-Up Study [HPFS]; Physician Health Study [PHS]), Sweden (Scandinavian Prostate Cancer Group Study [4SPCG-4] and TURPs Study) and Italy (Bologna Indolent Prostate Cancer Series). Her purpose in these studies has been to determine the Gleason score according to the new histopathological updates through analyzing the features of benign and pre-malignant lesions that lead to prostate cancer because a better statement of the histological Gleason grading is critical for understanding the biology behind prostate cancer.

Francesca Giunchi was also involved in the Prostate Cancer Foundation funded project entitled, “Shedding light on stromal – epithelial interactions in prostate cancer carcinogenesis and mortality,” led by the co-leaders of ToPCap, Dr. Massimo Loda and Dr. Lorelei Mucci.

Francesca Giunchi along with Michelangelo Fiorentino and Arrigo Bondi represent the Italian branch of the TopCap team in Europe. While she collaborates with a number of ToPCaP’s European members, Dr. Giunchi typically collaborates with Dr. Andren in Sweden and Dr. Finn in Ireland.